argenx is a biotech company focused on transforming immunology and delivering medicines for autoimmune patients. The company is led by VYVGART, a first-in-class neonatal Fc receptor blocker approved for the treatment of generalized myasthenia gravis (gMG), with potential applications across dozens of severe autoimmune diseases. argenx maintains its roots as a science-based start-up while undergoing multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets. The company emphasizes innovation across all business areas and builds partnerships to deliver more value for patients.
Industry
Biotechnology
Remote Policy
Hybrid
Beta · Sourced from candidate reports
Be the first to share your experience with argenx.
Your reply helps other candidates know what to expect.
